INCYTE/ US45337C1027 /
05/11/2024 19:27:52 | Chg. +21.43 | Volume | Bid20:30:00 | Ask20:30:00 | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
70.74EUR | +43.46% | 15 Turnover: 1,061.10 |
-Bid Size: - | -Ask Size: - | 14.99 bill.EUR | - | - |
GlobeNewswire
16/08
China Medical System (00867) Released its 2024 Interim Results: Steady Increase in Revenue and Profi...
GlobeNewswire
06/08
MacroGenics Provides Update on Corporate Progress, Second Quarter 2024 Financial Results
GlobeNewswire
01/08
Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update
GlobeNewswire
30/07
MacroGenics Announces Achievement of $100 Million in Milestones Related to Retifanlimab Collaboratio...
GlobeNewswire
25/06
China Medical System Completes Dosing of the First Subject in Phase III Bridging Trial of Ruxolitini...
GlobeNewswire
09/05
MacroGenics Provides Update on Corporate Progress, First Quarter 2024 Financial Results and Interim ...
GlobeNewswire
08/05
Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update
GlobeNewswire
02/04
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sin...
GlobeNewswire
01/04
CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast ...
GlobeNewswire
28/02
Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Up...
GlobeNewswire
09/01
Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030
GlobeNewswire
09/12/2023
CURE Media Group announces winners of the 2023 MPN Heroes® Recognition Program
GlobeNewswire
16/11/2023
CURE Media Group® announces Jane Fonda as keynote speaker for the 2023 MPN Heroes® recognition progr...
GlobeNewswire
02/11/2023
Merus Announces Financial Results for the Third Quarter 2023 and Provides Business Update